Edwards Lifesciences Corporation (EW)

NYSE: EW · IEX Real-Time Price · USD
82.46
-1.13 (-1.35%)
Sep 27, 2022 3:56 PM EDT - Market open
-1.35%
Market Cap 51.13B
Revenue (ttm) 5.36B
Net Income (ttm) 1.46B
Shares Out 619.94M
EPS (ttm) 2.33
PE Ratio 35.39
Forward PE 31.06
Dividend n/a
Ex-Dividend Date n/a
Volume 2,466,607
Open 84.34
Previous Close 83.59
Day's Range 81.87 - 84.60
52-Week Range 81.87 - 131.73
Beta 1.14
Analysts Buy
Price Target 118.72 (+44.0%)
Earnings Date Oct 25, 2022

About EW

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition,... [Read more...]

Industry Health Care Equipment & Supplies
IPO Date Mar 27, 2000
CEO Michael Mussallem
Employees 15,700
Stock Exchange NYSE
Ticker Symbol EW
Full Company Profile

Financial Performance

In 2021, EW's revenue was $5.23 billion, an increase of 19.29% compared to the previous year's $4.39 billion. Earnings were $1.50 billion, an increase of 82.55%.

Financial Statements

Analyst Forecast

According to 31 analysts, the average rating for EW stock is "Buy." The 12-month stock price forecast is 118.72, which is an increase of 43.96% from the latest price.

Price Target
$118.72
(43.96% upside)
Analyst Consensus: Buy
Stock Forecasts

News

EDWARDS ANNOUNCES SIX-MONTH DATA CONFIRMING TEER AS SAFE AND EFFECTIVE FOR DMR IN FIRST HEAD-TO-HEAD TRIAL

BOSTON , Sept. 17, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced results from CLASP IID, the first randomized controlled trial that directly compares two contemporary transc...

1 week ago - PRNewsWire

EDWARDS PASCAL PRECISION TRANSCATHETER VALVE REPAIR SYSTEM RECEIVES FDA APPROVAL FOR DEGENERATIVE MITRAL REGURGITATION

IRVINE, Calif. , Sept. 15, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system for transcatheter edge-to-ed...

1 week ago - PRNewsWire

Edwards Lifesciences (EW) Debuts SAPIEN 3 Ultra RESILIA Valve

Edwards Lifesciences' (EW) SAPIEN 3 Ultra RESILIA valve combines its breakthrough RESILIA tissue technology with the SAPIEN 3 Ultra transcatheter aortic heart valve.

2 weeks ago - Zacks Investment Research

EDWARDS LAUNCHES SAPIEN 3 ULTRA RESILIA VALVE FOLLOWING FDA APPROVAL

IRVINE, Calif. , Sept. 12, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced the launch of the SAPIEN 3 Ultra RESILIA valve, which incorporates Edwards' breakthrough RESILIA tissue te...

2 weeks ago - PRNewsWire

Edward Lifesciences (EW) Gains From New Products Amid Cost Woe

Edwards Lifesciences (EW) expects full-year 2022 underlying sales to grow on the back of strength in demand for products used in more intense surgeries.

2 weeks ago - Zacks Investment Research

OCPNY or EW: Which Is the Better Value Stock Right Now?

OCPNY vs. EW: Which Stock Is the Better Value Option?

3 weeks ago - Zacks Investment Research

Edwards Lifesciences Best Able to Withstand Medtech Slowdown, Says Analyst

Investors do not seem convinced that Edwards Lifesciences Corp. ( EW , Financial) is well equipped to handle a downturn in the medical device industry. Despite what one analyst thinks, the Irving, Calif...

1 month ago - GuruFocus

Edwards Lifesciences (EW) Gets CE Mark for PASCAL Precision

Edwards Lifesciences' (EW) PASCAL Precision system enables precise navigation and implant delivery during mitral and tricuspid regurgitation treatment.

1 month ago - Zacks Investment Research

EDWARDS PASCAL PRECISION TRANSCATHETER MITRAL AND TRICUSPID VALVE REPAIR SYSTEM RECEIVES CE MARK

IRVINE, Calif. , Aug. 17, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system received CE Mark for the trea...

1 month ago - PRNewsWire

Edwards Lifesciences (EW) Q2 Earnings Meet Estimates, Margins Up

Edwards Lifesciences (EW) posts Q2 earnings in line with the Zacks Consensus Estimate, with robust performances across all product groups driving the top line.

1 month ago - Zacks Investment Research

Edwards Lifesciences (EW) Matches Q2 Earnings Estimates

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 0% and 1.61%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Edwards Lifesciences Wipes Out Regular-Session Gains On 2022 Guidance Cut

Edwards Lifesciences cut its 2022 sales guidance, citing exchange-rate challenges and hospital staffing issues. EW stock tumbled.

1 month ago - Investors Business Daily

EDWARDS LIFESCIENCES REPORTS SECOND QUARTER RESULTS

IRVINE, Calif. , July 28, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2022.

1 month ago - PRNewsWire

Edwards Lifesciences (EW) to Post Q2 Earnings: What's in Store?

Edwards Lifesciences' (EW) Q2 performance will likely reflect the continued adoption of the RESILIA tissue valves and enhanced sales of the HemoSphere platform.

2 months ago - Zacks Investment Research

EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON JULY 28, 2022

IRVINE, Calif. , July 21, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2022 after the market closes on Thursday, July 28, 2...

2 months ago - PRNewsWire

4 Profitable Companies With Solid Financial Conditions

When screening the market for value opportunities, investors may want to consider stocks that represent companies with high profitability and robust financial conditions. The companies below meet these ...

Other symbols: GOOGMNSTVRTXGOOGL
2 months ago - GuruFocus

2 Medical Device Stocks With Extremely High GF Scores

The GF Score system from GuruFocus is a unique metric that takes into account a company's financial strength, profitability, growth, valuation and momentum to determine if the stock is likely to outperf...

Other symbols: ABMD
2 months ago - GuruFocus

Growth stocks remain resilient in weakening economy, says Neuberger's Jason Tauber

Jason Tauber, Neuberger Berman large cap disciplined growth and the disruptors portfolio manager, joins 'Closing Bell: Overtime' to discus his bullish case for the growth trade.

Other symbols: ARWRDHRDXCMLLYNBDS
2 months ago - CNBC Television

Here's Why You Should Retain Edwards Lifesciences (EW) Now

Investors are optimistic about Edwards Lifesciences' (EW) strong segmental performance and the growing demand for its RESILIA tissue valves.

2 months ago - Zacks Investment Research

OCPNY vs. EW: Which Stock Is the Better Value Option?

OCPNY vs. EW: Which Stock Is the Better Value Option?

3 months ago - Zacks Investment Research

Edwards Lifesciences' Unifying Generations Report Seeks to Transform Perceptions of the “Pivotal” 3rd Generation

NYON, Switzerland--(BUSINESS WIRE)--Edwards Lifesciences today published ‘Unifying Generations: Building the Pathway to Intergenerational Solidarity' – a report, based on a survey of 12,850 Europeans ac...

3 months ago - Business Wire

OCPNY vs. EW: Which Stock Should Value Investors Buy Now?

OCPNY vs. EW: Which Stock Is the Better Value Option?

3 months ago - Zacks Investment Research

Why Is Edwards Lifesciences (EW) Down 11.8% Since Last Earnings Report?

Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock?

4 months ago - Zacks Investment Research

EDWARDS LIFESCIENCES TO PRESENT AT THE BERNSTEIN 38TH ANNUAL STRATEGIC DECISIONS CONFERENCE

IRVINE, Calif. , May 23, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced it is scheduled to present at the Bernstein 38th Annual Strategic Decisions Conference on Thursd...

4 months ago - PRNewsWire

7 Growth Stocks That Analysts Love Right Now

These growth stocks are receiving buy ratings and significantly higher price targets from analysts, making them ideal names to consider. The post 7 Growth Stocks That Analysts Love Right Now appeared fi...

Other symbols: AMDENPHFTNTGNRCNVDAWBD
4 months ago - InvestorPlace